Dilon Diagnostics: Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer

CHICAGO, Nov. 30 /PRNewswire/ -- Dr. Jessica Torrente, Assistant Professor of Radiology at George Washington University Medical Center in Washington, D.C., demonstrated the integration and use of Breast-Specific Gamma Imaging (BSGI) in clinical practice as an adjunct imaging modality for the diagnosis of breast cancer today at the annual meeting of the Radiological Society of North America (RSNA).

The study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging technique. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as “hot spots” on the BSGI image. BSGI is a molecular imaging technique that can see lesions independent of tissue density and discover early stage cancers.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon’s cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.

Dilon Diagnostics

MORE ON THIS TOPIC